Scientists from Wroclaw University of Science and Technology are working on an innovative Alzheimer’s treatment that could revolutionize the fight against neurodegenerative disorders.
According to a statement from Wrocław University of Science and Technology, Dr. Marcin Poręba’s team Dr. hab. Marcin Poręba’s team focuses on developing a new class of therapeutics known as antibody-drug conjugates (ADCs). These innovative compounds aim to precisely target pathological features associated with Alzheimer’s disease, potentially leading to breakthrough results by minimizing side effects and enhancing treatment efficacy. According to Professor Marcin Poręba, these conjugates will target proteins responsible for the progression of Alzheimer’s disease.
Antibody-drug conjugates, already showing promise in oncology, consist of an antibody, a linker, and a drug, with the antibody serving both as a therapeutic agent and a carrier for the toxic drug, which is released in the tumor environment.
“Our conjugates will target proteins involved in disease progression, such as amyloid plaques (Aβ) and tau tangles. These pathological proteins accumulate in the brains of Alzheimer’s patients, leading to inflammation, synaptic dysfunction, and neuronal death,” said Poręba.
The project “First Antibody-Drug Conjugates in Alzheimer’s Disease Therapy” has received nearly 5 million PLN (1.2 million EUR) in funding from the National Science Centre.
Ph: Press materials from Wrocław University of Science and Technology.
Source:
Nauka w Polsce
PolskieRadio
